Erik R Nelson
Overview
Explore the profile of Erik R Nelson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mulligan M, Boudreau M, Bouwens B, Lee Y, Carrell H, Zhu J, et al.
ACS Cent Sci
. 2025 Mar;
11(2):228-238.
PMID: 40028352
Patients with estrogen receptor α positive (ERα+) breast cancer typically undergo surgical resection, followed by 5-10 years of treatment with adjuvant endocrine therapy. This prolonged intervention is associated with a...
2.
Bendre S, Wang Y, Hajyousif B, Rajendra K, K C R, Bhogale S, et al.
bioRxiv
. 2025 Mar;
PMID: 40027727
Although immune therapy has seen significant advances, the majority of breast and other solid tumors do not respond or quickly develop resistance. One factor driving resistance is highly immune suppressive...
3.
Wang Y, Bendre S, Krauklis S, Steelman A, Nelson E
Endocrinology
. 2025 Feb;
166(4).
PMID: 39951497
Cholesterol metabolism and homeostasis have emerged as important factors governing various aspects of cancer biology. Clinical associations between circulating cholesterol and poor prognosis or use of cholesterol-lowering medication and improved...
4.
Zuo Q, Yoo J, Nelson E, Sikora M, Riggins R, Madak-Erdogan Z
NPJ Breast Cancer
. 2025 Jan;
11(1):3.
PMID: 39809806
Patients with metastatic breast cancer face reduced quality of life and increased mortality rates, necessitating more effective anti-cancer strategies. Building on previous research that identified metastatic-niche-specific metabolic vulnerabilities, we investigated...
5.
Song Y, Shinn M, Bangru S, Wang Y, Sun Q, Hao Q, et al.
bioRxiv
. 2024 Nov;
PMID: 39554052
Hypoxia-induced alternative splicing (AS) regulates tumor progression and metastasis. Little is known about how such AS is controlled and whether higher-order genome and nuclear domain (ND) organizations dictate these processes....
6.
Das Gupta A, Park J, Sorrells J, Kim H, Krawczynska N, Pradeep D, et al.
Endocrinology
. 2024 Sep;
165(11).
PMID: 39298675
Extracellular vesicles (EVs) serve as crucial mediators of cell-to-cell communication in normal physiology as well as in diseased states; they have been largely studied in regard to their role in...
7.
Singh D, Cong Z, Song Y, Liu M, Chaudhary R, Liu D, et al.
Mol Cell Biol
. 2024 Aug;
44(9):372-390.
PMID: 39133105
A significant number of the genetic alterations observed in cancer patients lie within nonprotein-coding segments of the genome, including regions coding for long noncoding RNAs (lncRNAs). LncRNAs display aberrant expression...
8.
Krawczynska N, Wang Y, Lim K, Das Gupta A, Lenczowski A, Abughazaleh M, et al.
bioRxiv
. 2024 Aug;
PMID: 39131340
Small extracellular vesicles (sEVs) are emerging as critical mediators of intercellular communication in the tumor microenvironment (TME). Here, we investigate the mechanisms by which sEVs derived from neutrophils treated with...
9.
Vidana Gamage H, Albright S, Smith A, Farmer R, Shahoei S, Wang Y, et al.
Cancer Lett
. 2024 Jun;
597:217086.
PMID: 38944231
Immune checkpoint blockade (ICB) has had limited utility in several solid tumors such as breast cancer, a major cause of cancer-related mortality in women. Therefore, there is considerable interest in...
10.
Vidana Gamage H, Shahoei S, Wang Y, Jacquin E, Weisser E, Bautista R, et al.
Cancer Lett
. 2024 Jun;
597:217042.
PMID: 38908543
Although survival from breast cancer has dramatically increased, many will develop recurrent, metastatic disease. Unfortunately, survival for this stage of disease remains very low. Activating the immune system has incredible...